Namita Gandhi

Executive Director, Scientific Strategy & Communication (Research and Translational Medicine) @ Apogee Therapeutics

About

I am dedicated to pushing the boundaries of medical science and education. With over two decades of experience in biotech R&D, specializing in translational immunology and oncology, I have developed a distinct expertise in deciphering and communicating complex disease biology. My extensive study of over 100 diseases has equipped me to lead significant projects, including indication selection, disease strategy, roadmapping to clinical proof of concept, implementing biomarker strategy, and streamlining pre-clinical development. Among my career highlights is my pivotal role in determining the indications for Dupixent, illustrating my capacity to strategically align new assets with appropriate diseases. This success stems from my unique take on integrating basic, translational, and clinical insights, setting my work apart from conventional approaches and driving transformative outcomes for patients. Additionally, I am the founder of Nimitry Books, LLC, which aims to ignite a passion for science in young minds. My children’s books demystify immunology through compelling stories that engage and educate, inspiring the next generation about the wonders of the human body.

Country

United States

City

San Francisco Bay Area

Industry

Publishing

Skill

Benchmarking, Product Launch, Product Design, Generative AI, Business Strategy, Data Analysis, Consumer Insight, Competitive Intelligence, Microsoft Excel, Research Skills, Strategic Planning, Product Development, Startups, Strategic Partnerships, Cancer Research, Strategy, New Ventures, Clinical Monitoring, Regulatory Submissions, Analytical Skills

Experience

Executive Director, Scientific Strategy & Communication (Research and Translational Medicine)

Apogee Therapeutics

2024-11 - Present · 1 yr 10 mos

Scientific Strategy & Communication • Led and coordinated scientific and medical communication outputs for research and translational medicine teams at Apogee Therapeutics. • Collaborated with cross-functional teams to ensure a unified scientific voice across functions like Medical Affairs, BD, and Medical Writing. • Implemented strategies to enhance communication and streamline processes for efficient scientific and medical writing within Research and TM.

R&D Scientific Consultant | Biopharma and Biotech Start-up

2023-11 - 2024-11 · 1 yr 1 mo

Northern California

Streamlines product development by utilizing strategic insights and comprehensive skill sets in pre-clinical and clinical program management for biotechs; serves as disease domain expert integrating AI/ML and data science with biology. Services include Strategic Program Development, Thought Partner to C-Level, Preclinical and Translational Studies, Target evaluation, Indication Selection, Product Positioning and Testing, Blue Sky thinking and Solutions for Ambiguous Problems (that one is my favorite).

VP, Disease Area Strategy & Translational Biology

Hummingbird Bioscience

2020-1 - 2023-11 · 3 yrs 11 mos

San Francisco Bay Area

Adaptive leader that can flex from Research to Development roles to meet company needs; held titles in Disease Strategy, Translational Biology, Program Development Lead. Core strength in understanding disease mechanism, indication selection, apply & direct big data to gain insights into patient selection biomarkers, precedence analysis and conceptualizing innovative early development plans. Co-lead CSR committee

Experimental Drug Development Centre, Asset Development

A*STAR - Agency for Science, Technology and Research

2019-3 - 2020-1 · 11 mos

Singapore

Director, Clincial Sciences

Regeneron

2017-2 - 2018-1 · 1 yr

Tarrytown, New York

Contribute scientifically and strategically to clinical development of late-staged assets in Immune and Inflammation portfolio (e.g. dupilumab, sarilumab)

Director, Translational Medicine

Regeneron

2007-12 - 2017-2 · 9 yrs 3 mos

Tarrytown, NY

Provided scientific and strategic insights to advance over 6 antibody programs (e.g. IL-4R, IL-6R, IL-33, RSV, anti-allergens) from discovery to late stage clinical development for Immunology, Inflammation & Infectious Disease therapeutic areas.

Clinical Research Scientist

Vanda Pharmaceuticals

2005-6 - 2007-11 · 2 yrs 6 mos

Maryland

Served multiple functions from operational oversight to clinical/regulatory strategy of global Phase 3 small molecule program and subsequent new drug application for in-licensed legacy asset (iloperidone, Fanapt) at pre-IPO start-up.